PPARA and breast carcinoma: Pioglitazone, not in clinical trials against breast cancer, induces, in vitro, G0/G1 arrest via increasing p21 and p27 in MAPK-dependent/partly PPAR-independent manner in MCF7 breast cancer cells [113].